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DNA shuffling and directed evolution were employed 
to develop a novel adeno-associated virus (AAV) vector 
capable of crossing the seizure-compromised blood–
brain barrier (BBB) and transducing cells in the brain. 
Capsid DNA from AAV serotypes 1–6, 8, and 9 were shuf-
fled and recombined to create a library of chimeric AAVs. 
One day after kainic acid–induced limbic seizure activity 
in rats, the virus library was infused intravenously (i.v.), 
and 3 days later, neuron-rich cells were mechanically 
dissociated from seizure-sensitive brain sites, collected 
and viral DNA extracted. After three cycles of selection, 
green fluorescent protein (GFP)–packaged clones were 
administered directly into brain or i.v. 1 day after kainic 
acid–induced seizures. Several clones that were effective 
after intracranial administration did not transduce brain 
cells after the i.v. administration. However, two clones 
(32 and 83) transduced the cells after direct brain infu-
sion and after i.v. administration transduced the cells 
that were localized to the piriform cortex and ventral 
hippocampus, areas exhibiting a seizure-compromised 
BBB. No transduction occurred in areas devoid of BBB 
compromise. Only one parental serotype (AAV8) exhib-
ited a similar expression profile, but the biodistribution 
of 32 and 83 diverged dramatically from this parental 
serotype. Thus, novel AAV vectors have been created 
that can selectively cross the seizure-compromised BBB 
and transduce cells.
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IntroductIon
Recent studies have established the potential of viral vector gene 
therapy as a viable treatment option for intractable epilepsy. 
Adeno-associated virus (AAV)–mediated expression and constitu-
tive secretion of the neuroactive peptide, galanin, attenuates focal 
seizure sensitivity, prevents seizure-induced neuronal cell death, 
and blocks kainic acid–induced limbic seizure activity.1,2 Similarly, 
studies by Richichi et al.3 have shown that AAV-mediated expres-
sion of prepro-neuropeptide Y exerts a range of antiseizure effects 
that include increasing the electrical seizure threshold in the hip-
pocampus and significantly retarding the rate of kindling epilep-
togenesis. Although a number of additional viral vector–based 
approaches have exhibited varying degrees of antiseizure success 
(for review see ref. 4), for any of these approaches the clinical 
application would entail microinfusion of the viral vectors directly 
into brain areas that exhibit identified seizure activity.
Recent advances in AAV engineering techniques have vastly 
expanded the ability to develop novel AAV serotypes. When com-
bined with directed evolution where specific characteristics can be 
selected without a priori knowledge of the physical determinants, 
novel vectors can be identified that exhibit the desired, specific 
tropisms. As an initial proof of principle, Maheshri et al.5 intro-
duced random changes in the AAV2 capsid by error-prone PCR 
and then selected novel AAV vectors that lacked heparin-binding 
properties or evaded the in vivo immune response. More recently, 
Li et al.6 utilized DNA shuffling of AAV capsid genes from a num-
ber of serotypes and directed evolution to identify a novel chi-
meric serotype that exhibited increased efficacy for melanoma 
cell transduction. Thus, by using a combination of AAV capsid 
DNA shuffling and directed evolution one can select mutants that 
exhibit specific, desirable properties.
Given these recent advances in AAV vector engineering, 
development of an alternative, peripheral therapeutic approach 
to epilepsy might be attained by taking advantage of the fact that 
seizures compromise the blood–brain barrier (BBB). Although 
the BBB tightly controls the movement of molecules both into 
and out of the brain,7 evidence has accumulated in both experi-
mental animals and epileptic patients that seizures cause a local 
compromise in BBB function.8–13 This compromise in the BBB 
leads to the extravasation of large molecules such as albumin into 
the parenchyma of the brain.13 If viral vectors could be developed 
that selectively cross this seizure-compromised BBB and trans-
duce cells in the area of compromise, one potentially would have 
a therapeutic conduit to those areas of brain involved in seizure 
generation.
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The following studies utilized AAV capsid DNA shuffling and 
subsequent directed evolution in order to identify novel clones 
that exhibited the ability to cross the seizure-compromised BBB 
after intravenous (i.v.) administration and subsequently trans-
duce cells in the central nervous system (CNS). The generation 
of such mutant AAV vectors would establish the possibility to 
deliver a therapeutic gene to areas of seizure activity using periph-
eral administration instead of direct microinfusion into the brain 
parenchyma.
results
Kainic acid seizure–induced compromise of the BBB
In order to validate that indeed the kainic acid–induced sei-
zures caused a compromise in the BBB at the time of library 
administration, rats were treated with kainic acid (10 mg/kg, 
 intraperitoneally) where class IV limbic seizure activity developed 
over a period of 70–100 minutes post-treatment. Twenty-four hours 
after the appearance of the first class IV seizure, intracardiac infu-
sion of fluorescein isothiocyanate–conjugated bovine serum albu-
min revealed specific areas of BBB compromise similar to previous 
findings with pilocarpine-induced limbic seizures10 (Figure 1). 
More importantly, the areas of BBB compromise were primarily 
localized to areas known to modulate the kainic acid–induced sei-
zure activity, such as the piriform cortex and hippocampus.
directed evolution and recovery of chimeric clones
As previously described,6 the initial chimeric library was com-
posed of shuffled capsids from AAV serotypes 1–6, 8, 9, and an 
AAV8 with E531K mutation. This infectious and replication-
competent library was injected (0.5 ml; 1.6 × 1013 viral particles/
kg) into the tail vein of rats 24 hours after kainic acid induction 
of class IV limbic seizure activity. Three days later, cells were 
mechanically dissociated from the piriform cortex and the hip-
pocampus as previously described14 (Supplementary Figure S1), 
and viral capsid DNA was extracted from these neuron-rich sam-
ples. The pooled PCR products were cloned back into a wild-type 
(WT) AAV backbone (pSSV9) and pooled clones were used to 
generate the next round’s starting library. This selection process 
was repeated two times and then individual clones were made 
into recombinant virus that contained a green fluorescent protein 
(GFP) reporter gene. A total of three rounds of selection were per-
formed, and a sampling of clones was sequenced after each round 
of selection (Figure 2, Supplementary Table S1). We observed 
several instances where multiple clones had identical overall sero-
type composition but contained silent, missense, and nonsense 
point mutations throughout the capsid gene. In an assay for the 
Figure 1 Blood–brain barrier integrity is disrupted 24 hours after 
kainic acid administration and class IV seizures. Confocal micrographs 
of cerebral blood vessels perfused with fluorescein isothiocyanate– 
albumin illustrating irregular, cloud-like patches of albumin leakage in 
the (a) piriform cortex and (b) ventral hippocampus. Inset in b shows 
magnified image of microvascular compromise in the ventral hippocam-
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Figure 2 directed evolution and recovery of chimeric clones. (a) Using a shuffled library based on adeno-associated virus (AAV) 1–6, 8, and 9, a 
directed evolution strategy was employed to select for an AAV capsid that can cross the seizure-compromised blood–brain barrier (BBB) and transduce 
cells in the areas of seizure influence. (b) Viable recovered clones that were tested in these studies. The scale at the top corresponds to the amino acid 
residues, with start sites for VP1, VP2, and VP3 indicated. A color-coding scheme is used to indicate the overall serotype composition at each location, 
and graded colors within each clone indicate regions of shared identity between neighboring serotypes. Where AAV1 and 6 are indistinguishable by 
amino acid sequence, a double stripe is drawn. Missense point mutations are shown as thin vertical lines, with the color corresponding to a serotype 
with that amino acid or a black line to indicate an amino acid not present in any parent. To the right of each amino acid map is the number assigned 
to that clone and the round from which it was recovered (in parentheses). wt, wild type.
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ability of the recovered clones to make virus equivalent to AAV2, 
only 14–27% of recovered clones were viable (Supplementary 
Table S1). The presence of multiple point mutations and the lim-
ited viability of recovered clones suggest that the PCR recovery 
step was mutagenic. Thus, not only did these mutations likely 
influence the ability to package recombinant virus, but PCR point 
mutants also provided additional capsid variability beyond the 
original input library. In the VP3 region of the capsid where the 
surface would be exposed for receptor interaction,15 the capsids 
were primarily composed of AAV1, 8, and 9 (Figure 2).
In vivo assessment of transduction efficacy  
after direct infusion into the brain
A number of recombinant clones (packaging self-complementary 
chicken β actin-GFP genomes), were infused into the rat piriform 
cortex (1 µl) to test the ability to transduce cells in the brain. This 
initial test was conducted, because a clone incapable of transduc-
ing CNS cells after direct administration certainly would not be 
expected to transduce cells after peripheral administration. Clone 
83 (2.1 × 1012 viral genomes/ml) exhibited substantial transduction 
in the piriform cortex, whereas clone 32 (2.8 × 1012 viral genomes/
ml) exhibited more moderate levels of transduction (Figure 3a,b). 
Clones 74 (3.3 × 1011 viral genomes/ml) and 84 (1.1 × 1011 viral 
genomes/ml) also transduced cells in the piriform cortex, although 
not to the same degree as clones 32 and 83 (Figure 3c,d). In all 
cases, the majority of the transduced cells exhibited a morphology 
resembling neurons. The titer attained for clone 3 was 1.2 × 1011 
viral genomes/ml, and after direct piriform cortex infusion, no 
transduction was found. Because this infusion of clone 3 was not 
sufficient to transduce cells upon direct infusion into the CNS, fur-
ther studies were not conducted with this clone.
In vivo assessment of transduction patterns  
after postseizure i.v. administration
When the various AAV clones were infused i.v. (0.5 ml) 24 hours 
after kainic acid–induced seizures in rats, a unique pattern emerged. 
I.v. administration of clones 74 (7.8 × 1011 viral genomes/ kg) and 
84 (3.8 × 1012 viral genomes/kg) did not result in any transduced 
cells in the brain 2 weeks after vector administration (data not 
shown). In marked contrast, post-seizure, i.v. administration 
of clone 32 (5.4 × 1012 viral genomes/kg) resulted in a number 
of GFP-positive cells that were confined to the piriform cortex 
(Figure 4a). More impressively, postseizure i.v. administration of 
clone 83 (3.5 × 1012 viral genomes/kg) caused substantial trans-
duction of cells throughout the anterior–posterior extent of the 
piriform cortex, as well a number of cells in the ventral hippocam-
pus (Figure 4b–f). For both clones 32 and 83, no transduced cells 
occurred in brain areas that are normally not associated with sei-
zures or seizure-induced BBB compromise, such as the striatum 
and hypothalamus.8,10
Because the predominant composition of clones 32 and 83 
included portions from AAV1, 8, and 9, these parental serotypes 
were evaluated. Certainly recent studies have demonstrated that 
AAV9 can cross the intact BBB.16,17 As would be expected, all three 
serotypes effectively transduced cells in the piriform cortex after 
direct infusion (Supplementary Figure S2). I.v. administration 
of AAV1 (2.1 × 1012 viral genomes/kg) 1 day after kainic acid–
induced seizures resulted in sporadic GFP-positive neurons and 
glia in the paraventricular nucleus, hippocampus (Figure 5a,b), 
and piriform cortex. However, widely dispersed, cerebrovascu-
lar endothelial cells comprised the vast majority of GFP-positive 
cells (Figure 5c). In contrast, the same i.v. protocol with AAV8 
(7.8 × 1012 viral genomes/kg) produced a pattern of transduction 
that was very similar to the pattern seen after i.v. administration 
of clones 32 and 83. GFP-positive cells were found in the piri-
form cortex and the hippocampus, whereas only a few scattered 
cells were found in brain areas with an intact BBB (Figure 5d–f). 
Finally, after kainic acid–induced seizures i.v. administration of 
AAV9 (4.3 × 1012 viral genomes/kg) resulted in sparse, widely 
scattered GFP-positive cells across a wide range of brain structures 
(Figure 5g–i). Although the ability of AAV9 to cross the intact 
BBB agrees with previous studies,16,17 the lower dose employed 
Clone 83 Clone 32 Clone 84 Clone 74
Figure 3 Immunohistochemical analysis of green fluorescent protein transgene expression, 2 weeks following injections of infectious clones 
into piriform cortex. (a–d) Low-power photomicrographs of representative coronal sections showing the maximal dorsoventral extent of transduc-
tion around the site of injection. Bar = 1 mm for a–d at equal magnification. (e–h) Higher power images from sites depicted in a–d, demonstrating 
predominant neuronal tropism. Bar = 50 µm for e–h at equal magnification. (a,e) Clone 83; (b,f) clone 32; (c,g) clone 84; (d,h) clone 74.
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in this study (4.3 × 1012 viral genomes/kg) transduced far fewer 
cells than previously reported for a higher dose of AAV9 (2 × 1014 
viral genomes/kg) (ref. 16). Moreover, in contrast to AAV8, AAV9 
transduced only a few widely scattered cells in the entire piriform 
cortex.
Double-label immunofluorescence shows that clone 83 
transduced both oligodendrocytes and neurons (Figure 6a,b). 
However, no GFP colocalization was found with astrocytes 
or microglia (data not shown). Similarly, double-label immu-
nofluorescence shows that after i.v. AAV8 administration GFP 
expression colocalized predominantly with neurons and oligo-
dendrocytes (Figure 6c,d). For AAV1, the vast majority of GFP-
positive cells colocalized with RECA-1, a marker for endothelial 
cells (Figure 6e).
Figure 5 transduction patterns of adeno-associated virus (AAV)1, 8, and 9 in rat brain 2 weeks after class IV seizures and intravenous vector 
administration. (a–c) Systemic injection of AAV1 resulted in transduction of endothelial cells predominantly, with sporadic labeling of neurons and 
glia throughout the brain. (a) Neurons in the paraventricular nucleus of the hypothalamus; (b) green fluorescent protein (GFP)-labeled cells (presum-
ably astrocytes) surrounding a blood vessel in the hippocampus; (c) endothelial cells lining a capillary in the motor cortex. (d–f) Intravenous injection 
of AAV8 resulted in a pattern of GFP labeling that was similar to, but more widespread than clones 32 and 83. (d) Middle piriform cortex, 2.2 mm 
posterior to bregma; (e) caudal piriform cortex, 3.2 mm posterior to bregma; (f) neuron-like cells in the medial preoptic nucleus of the hypothalamus. 
(g–i) Systemic injection of AAV9 resulted in scattered GFP-labeled cells throughout the brain. (g) Cells with glial and neuronal morphology in motor 
cortex; (h) a cluster of neurons in the nucleus of the horizontal limb of the diagonal band; (i) neurons in the dorsal hippocampus. Bar = 100 µm for 
all panels.
Figure 4 transduction patterns of clones 32 and 83 in rat brain two weeks after class IV seizures and intravenous vector administration. 
(a) Representative coronal section illustrating green fluorescent protein (GFP)–positive cells transduced by clone 32. Although not shown here, sys-
temic injection of clone 32 results in GFP-positive cells throughout the rostro-caudal extent of the piriform cortex. (b–f) After intravenous injection of 
clone 83, GFP-positive cells were found in greater numbers compared to clone 32 throughout the full rostral–caudal extent of the piriform cortex as 
well as in the ventral hippocampus. (b) rostral piriform, 1.0 mm and (c) 0.2 mm anterior to bregma; (d) middle piriform, 2.2 mm posterior to bregma; 
(e) caudal piriform, 3.6 mm posterior to bregma; (f) and ventral hippocampus, 5.8 mm posterior to bregma. Bar = 100 µm for all panels.
574 www.moleculartherapy.org  vol. 18 no. 3 mar. 2010 
© The American Society of Gene & Cell Therapy
Directed Evolution and the Seizure-compromised BBB
Biodistribution of clones 32 and 83
To assess the biodistribution of clones 32 and 83 compared to their 
parent serotypes, 5 × 1010 viral genomes of AAV1, 8, 9, clone 32, 
or clone 83 (packaging self-complementary chicken β actin-GFP 
genomes) was injected via the tail vein of adult mice (N = 3/group). 
This 2.5 × 1012 viral genome/kg body-weight dose was somewhat 
lower than the dose used in Figure 4 rat studies, but was required in 
order to deliver equivalent doses across all vectors. Biodistribution 
of GFP relative to mouse genomic DNA in the liver, heart, lung, 
kidney, spleen, skeletal muscle (gastrocnemius), and brain was 
performed using quantitative PCR (qPCR). Compared to AAV1, 
8, and 9, clones 32 and 83 had very limited tropism for all organs 
tested except the spleen and kidney (Figure 7; Supplementary 
Tables S2 and S3). For example, the liver concentration of clone 
83 was 30-fold lower than AAV1, 250-fold lower than AAV9, and 
1,100-fold lower than AAV8 (Supplementary Table S2). These 
results suggest that clones 32 and 83 are detargeted from most sys-
temic organs beyond that of the parent serotypes. Furthermore, 
the relative lack of clones 32 and 83 in the brain indicate that these 
clones do not cross the intact BBB.
dIscussIon
The results from these studies clearly illustrate the vast potential 
of combining AAV capsid DNA shuffling with directed evolu-
tion in the CNS. The in vivo selection process was designed to 
be very stringent where only those capsid clones that crossed the 
seizure-compromised BBB would be recovered. Indeed clones 32 
and 83 exhibited transduction patterns that proved localized to 
brain areas that experience a seizure-compromised BBB, though 
clone 83 appeared to transduce substantially more cells than clone 
32. As importantly, these clones did not transduce cells in areas 
of the brain that do not exhibit a seizure-induced compromise in 
the BBB, such as the striatum or hypothalamus. Another unin-
tentional but beneficial outcome involved the biodistribution pat-
terns. Clones 32 and 83 lost the parental tropism for non-CNS 
organs, such as the heart, lung, and liver. By testing the paren-
tal serotypes that compose clones 32 and 83, it appears that the 
shuffling and selection process combined the ability of AAV8 to 
gain CNS access through the seizure-compromised BBB with the 
peripheral organ detargeting properties of AAV1.
The success of this CNS selection process depended on a 
unique combination of two crucial elements. In a number of pre-
vious studies where the selection occurred in vitro, the library 
clones were rescued and amplified using WT adenovirus.6,18 Even 
when clones were rescued in vivo using a “biopanning” technique, 
animals were infected with WT adenovirus in order to rescue 
the AAV clones.18 This use of WT adenovirus was not practical 
in the CNS for two reasons. First, WT adenovirus would need to 
be injected directly into the CNS, but soon after direct injection 
adenovirus toxicity would kill many if not most of the infected 
cells (T.J. McCown and R.J. Samulski unpublished results). 
Second, even if some cells survived the WT adenovirus infection, 
the selection process would be extremely biased by the specific 
cellular tropism of adenovirus in the CNS. Thus, mutant AAV 
rescue from the CNS required PCR techniques. Another key ele-
ment involved the tissue selection. Even though several previous 
peripheral shuffling/directed evolution studies have used PCR res-
cue techniques, these investigations extracted DNA from whole 
organs19 or intact tumors.20 Whole-tissue extraction in the CNS, 
however, would include not only all CNS cells, but also endothe-
lial cells of the cerebral vasculature. Thus, it would be possible to 
select a mutant AAV that targets the cerebral vasculature. In order 
to circumvent this problem, cells were mechanically dissociated 
from seizure-sensitive areas of the CNS, and the viral DNA was 
extracted. This approach allowed the extraction and amplification 
of AAV DNA from neuron-rich, site-specific cell populations. 
Given that the virus DNA was amplified by PCR, however, it must 
be emphasized that the vectors were not selected for their ability 
to transduce neurons per se, but only on their ability to penetrate 
Figure 6 clone 83 and adeno-associated virus (AAV)8 transduce 
neurons and oligodendrocytes, whereas AAV1 transduces primar-
ily endothelial cells after intravenous administration and kainic acid 
injection. Fluorescence confocal micrographs illustrating clone 83- 
transduced cells [green fluorescent protein (GFP), green] colabel (a) with 
the neuronal marker NeuN in ventral hippocampus, and (b) with the oli-
godendrocyte markers Olig1 and Olig2 in the piriform cortex. Colabeling 
of GFP transduced by (c) AAV8 with NeuN, and (d) with Olig1 and 
Olig2, both in the piriform cortex. (e) The endothelial marker RECA-1 
colocalizes with GFP-positive cells transduced by AAV1 in a large blood 
vessel near the cortical surface. Bar = 50 µm for all panels.
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the compromised BBB and bind to cells in regions modulating 
seizure activity. Thus, we likely recovered some clones that can 
bind to neurons and other contaminating cells but have defects in 
cellular entry, trafficking, or uncoating. For this reason, multiple 
clones needed to be screened rather than continuing the selection 
until clonal homogeneity was attained. Clearly, the present find-
ings validate the utility of this approach.
Four previously published studies have described some level 
of AAV delivery to the adult rodent brain after i.v. injection of 
naturally occurring AAV vectors. Foust et al.16 and Duque et al.17 
delivered high doses (2 × 1014 vector genomes/kg and 1 × 1014 vec-
tor genomes/kg, respectively) of recombinant AAV9 (rAAV9) to 
achieve widespread transduction of cells throughout the brain. 
Towne et al.21 injected 1 × 1013 vector genomes/kg of rAAV6 to 
achieve a lower level of widespread brain transduction, whereas 
more recently McCarty et al.22 found widespread brain transduc-
tion by optimizing the time interval between mannitol BBB dis-
ruption and subsequent i.v. rAAV2 administration (2 × 1013 vector 
genomes/kg). Although in all of these cases substantial transduc-
tion was achieved, the patterns of transduction lacked any regional 
specificity. In contrast, clones 32 and 83 only transduced cells in 
areas known to experience seizure-induced BBB compromise. 
This specific pattern would restrict gene expression to those areas 
of seizure-induced pathology, a property that should minimize 
unwanted side effects. Also, in the case of clone 83, this selective 
transduction was achieved using 3.5 × 1012 vector genomes/kg, a 
dose that contained 3- to 60-fold fewer viral particles, when com-
pared to these previous studies.
Another beneficial property of clones 32 and 83 involves the 
dramatic divergence in biodistribution from that of the parental 
serotypes. Unlike AAV8 or 9, clones 32 and 83 exhibited virtu-
ally no tropism for the liver, heart, muscle, or lung. Also, although 
AAV1 exhibits a biodistribution that is similar to clones 32 and 
83, the liver concentration of clone 83 was 30-fold less than the 
AAV1 concentration (0.12 genomes/cell versus 3.87 genomes/cell; 
Supplementary Table S2). This substantial reduction in periph-
eral biodistribution proves to be quite important in light of stud-
ies on AAV-mediated liver transduction. In recent clinical trials 
for hemophilia B, when rAAV2/factor IX vector was delivered to 
the liver at doses of 4 × 1011 vector genomes/kg or 2 × 1012 vec-
tor genomes/kg, an asymptomatic immune response to the capsid 
cleared the vector and the accompanying gene expression.23,24 
Furthermore, in nonhuman primates intraportal administration 
of rAAV7 at doses ranging from 0.7 to 3.5 × 1012 vector genomes/
kg provoked a cytotoxic T-cell response, which led to a loss of 
transgene expression.25 In a separate clinical trial for hemophilia 
B, this immune response was not observed in the muscle at doses 
up to 1.8 × 1012 vector genomes/kg, where the rAAV2 vector was 
well tolerated and transgene expression persisted for over 3 years 
(ref. 26). These findings suggest that liver transduction likely 
poses a major barrier to systemic delivery in humans. The appar-
ent inability of clones 32 and 83 to accumulate in the liver should 
minimize immune responses to these mutant AAV vectors follow-
ing peripheral administration.
Tests of the parental serotypes provided important insight into 
the structural features of the capsid that allowed the mutant AAV 
vectors to cross a seizure-compromised BBB, as well as detarget 
peripheral organs. I.v. administration of AAV8 after kainic acid–
induced seizures produced a pattern of CNS transduction that 
was highly similar to the pattern produced by clones 32 and 83. 
Thus, it appears that the AAV8 component of clones 32 and 83 
conveys the ability to cross the seizure-compromised BBB. This 
conclusion is reinforced by the observation that clones 32 and 83 
were the only clones where the AAV8 component extended to the 
C-terminus of VP3. Although cerebrovascular endothelial cells 
comprised the dominant cell type transduced by AAV1 after i.v. 
administration, AAV1 exhibited a biodistribution pattern that 
was far more similar to clones 32 and 83 than to AAV8 and 9. 
Thus, the AAV1 portion of clones 32 and 83 likely contributed to 
this peripheral detargeting. However, the concentration of clone 
83 was significantly lower than that of AAV1 in all organs tested 
except the spleen and gastrocnemius muscle (Supplementary 
Table S3). Therefore, other factors, such as PCR point mutations, 
also must contribute to the peripheral detargeting of clone 83.
In conclusion, the application of AAV capsid DNA shuffling 
and directed evolution allowed the identification of two mutant 
AAV clones that upon i.v. administration, selectively cross the 
 seizure-compromised BBB and transduce cells. Coincident with 
0 0
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Figure 7 Biodistribution of clones 32 and 83. Mice were injected intravenously with 5 × 1010 vector genomes of each serotype, then after 10 
days the mice were killed and DNA was isolated from the brain, heart, liver, spleen, lung, kidney, and gastrocnemius muscle. Values were calcu-
lated as copies of GFP per diploid copy of mouse genomic DNA (laminB2 locus). (a) Spleen, lung, brain, kidney, heart, and gastrocnemius muscle. 
(b) Biodistribution in liver (note difference in scale). Error bars indicate standard deviation. Numerical values for all groups and P values are provided 
in Supplementary Tables S2 and S3, respectively.
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this property was the unexpected but advantageous finding 
that these clones also exhibit a unique, favorable biodistribu-
tion. Future studies will focus on both the therapeutic efficacy of 
peripheral administration, as well as further mutagenesis focused 
on increasing the transduction efficacy. Thus, these studies not 
only illustrate the power of combining capsid DNA shuffling and 
directed evolution, but also provide a potentially novel avenue of 
seizure gene therapy.
MAterIAls And Methods
DNA shuffling and directed evolution. The original library used con-
sisted of shuffled capsids from AAV serotypes AAV serotypes 1–6, 8, 9, 
and an AAV8 with E531K mutation. It was produced exactly as previously 
described.6 Rats received an injection of kainic acid (10 mg/kg, intraperi-
toneally), and within 70–100 minutes after kainic acid treatment, the rats 
exhibited class IV limbic seizure activity as described by Racine27 (raising up 
with forelimb clonus). Approximately 24 hours after kainic acid treatment, 
the shuffled library was injected into the tail vein (0.5 ml). Three days later, 
the rats were killed and cells were mechanically dissociated from the piri-
form cortex and dorsal hippocampus of 400-μm thick brain slices as previ-
ously described.14 Briefly, the slices were transferred to a recording chamber 
containing HEPES-buffered artificial cerebrospinal fluid (145 mmol/l NaCl, 
5 mmol/l KCl, 10 mmol/l HEPES, 2 mmol/l CaCl2, and 10 mmol/l glucose, 
pH 7.4: 340 mOsM/l). Then, a 0.3-mm glass probe was lowered to just 
touch the surface of the submerged tissue over either the pirirform cortex 
or the dorsal hippocampus. The probe was vibrated using a piezoelectric 
transducer (~0.5 mm amplitude at 10–50 Hz) for 2 minutes. The dissoci-
ated cells were collected from the artificial cerebrospinal fluid. DNA was 
recovered from neuron-rich samples using a DNeasy blood and tissue kit 
(cat. no. 69506; Qiagen, Valencia, CA) and subsequently concentrated by 
ethanol precipitation. Error-prone PCR was employed to further diversify 
the library between rounds, using the Expand Long Template PCR System 
(cat. no. 11681834001, low starting template, 50 cycles; Roche, Indianapolis, 
IN) with primers previously described.6 The pooled PCR products were 
cloned back into a WT AAV backbone (pSSV9) and pooled clones were 
used to generate the next round’s starting library. Pooled clones were trans-
fected into HEK293 cells with an adenovirus helper plasmid (pXX680) and 
a 10-fold excess of pXR2 containing AAV2 Rep and Cap. By this method, 
chimeric capsid genomes were packaged into mostly AAV2 capsids. The 
infectious titer of the AAV2-encapsidated chimeric library was determined 
using an infectious center assay.28 Then, the AAV2-encapsidated chimeras 
were added to HEK293 cells at a multiplicity of infection of 0.5 with WT 
adenovirus at a multiplicity of infection of 5 to predominantly package each 
chimeric AAV genome in its own capsid. After 72 hours, the cells were har-
vested and the virus purified as described28 and titered by qPCR. A total of 
three rounds of selection were performed. A sampling of recovered capsids 
after each round were subcloned into rAAV pXR2 backbones and SSV9 
replication-competent backbones and sequenced.
Viability of recovered clones. Due to the mutagenesis introduced dur-
ing PCR capsid recovery, many of the recovered capsids were defective 
for viral production. The recovered capsid sequences were screened for 
those able to produce virus. Approximately 60% confluent HEK293 cells 
in 24-well plates were transfected with the adenovirus helper plasmid 
pXX680 and pSSV9-based plasmids containing either AAV2 capsid or 
individual recovered chimeric capsids. pXX680 was co-transfected with 
pUC18 as a negative control. After 72 hours, cells were harvested and 
pelleted, then resuspended in 100 μl DNase I digestion buffer (10 mmol/l 
Tris–HCl, pH 8; 10 mmol/l MgCl2, 2 mmol/l CaCl2). After three freeze/
thaw cycles (−80 °C for 15 minutes, 50 °C for 30 minutes), the lysate was 
centrifuged at 13,000 rpm for 10 minutes and the supernatant retained. 
Lysates were incubated with 2 μl DNase I at 37 °C for 2 hours to remove 
unincorporated genomes, and then the reactions were stopped by adding 
6 μl 0.5 mol/l EDTA and boiling for 10 minutes. A volume of 92 μl of 
Proteinase K solution (1 mol/l NaCl, 1% sarkosyl, 0.1 mg/ml Proteinase 
K) was added to each tube, and incubated at 50 °C for at least 2 hours to 
liberate the viral genomes. The reaction mixtures were diluted 1:1,000 and 
1:10,000 in water and used directly as template for qPCR reactions. Those 
clones showing titers equivalent to pSSV9 (AAV2) were considered viable 
for production of virus.
Production of rAAV. rAAV vectors lack the Rep and Cap genes necessary for 
competent, independent replication, and the rAAV vectors were produced 
by the University of North Carolina Vector Core using a triple-transfection 
method in HEK293 cells as described.28 All recombinant vectors pack-
aged self-complementary genomes with enhanced GFP under the control 
of a miniature chicken β actin promoter and cytomegalovirus enhancer. 
Highly pure recombinant virus containing self-complementary genomes 
were recovered using two sequential CsCl gradients; then the peak frac-
tions were dialyzed in phosphate-buffered saline (PBS) containing 5% 
D-sorbitol. Viral titers were determined by both dot blot28 and qPCR.
CNS site microinfusions. All care and procedures were in accordance 
with the Guide for the Care and Use of Laboratory Animals [DHHS pub-
lication no. (NIH)85-23], and all procedures received prior approval by 
the University of North Carolina Institutional Animal Care and Usage 
Committee. The animals were pathogen-free male Sprague-Dawley rats 
(250–350 g) obtained from Charles River Laboratories (Wilmington, MA). 
The animals were maintained in a 12-hour light–dark cycle and had free 
access to food and water. For virus vector infusions, the rats (N = 2 per 
vector) were first anesthetized with 50 mg/kg pentobarbital and placed into 
a stereotaxic frame. Using a 32-gauge stainless steel injector and a Sage 
infusion pump, animals received 1 µl of each vector (clones 3, 32, 74, 83, 
84, AAV1, 8, or 9) over 10 minutes into the piriform cortex (interaural line 
6.7 mm, lateral 6.0 mm, vertical 7.4 mm, according to the atlas of Paxinos 
and Watson29). The injector was left in place for 5 minutes after infusion 
to allow diffusion from the injectors. The incision was sutured, and the 
animals were allowed 2 weeks to recover.
Immunohistochemistry, microscopy, and image processing. To assess 
BBB integrity, rats were deeply anesthetized with 100 mg/kg pentobarbital 
intraperitoneally 24 hours after kainic acid seizure induction. Subsequently, 
the rats (N = 3) were infused intracardially with 10 ml/kg fluorescein 
isothiocyanate–albumin (5 mg/ml; Sigma, St Louis, MO) as previously 
described.10 The brains were removed and immediately immersed into 
a solution of 4% paraformaldehyde in 100 mmol/l phosphate buffer (pH 
7.4). After immersion fixation for 48 hours at 4 °C, 40-µm thick coronal 
sections were cut using a vibrating blade microtome and mounted onto 
glass slides. Fluorescein isothiocyanate fluorescence was visualized by con-
focal microscopy as described below.
Two weeks after intracerebral or intravascular injection of shuffled 
clones, animals received an overdose of pentobarbital (100 mg/kg 
intraperitoneally) and were perfused transcardially with ice-cold 
100 mmol/l sodium PBS (pH 7.4), followed by 4% paraformaldehyde in 
phosphate buffer (pH 7.4). After brains were postfixed 12–48 hours at 4 °C 
in the paraformaldehyde–phosphate buffer, 40-µm thick coronal sections 
were collected as described above and subjected to immunohistochemical 
processing for GFP and neural cell markers.
Colorimetric GFP detection was performed by incubating free-
floating sections with a rabbit polyclonal antibody to GFP (1:500; 
Millipore, Billerica, MA). Briefly, sections were blocked in 10% normal 
goat serum and 0.1% Triton X-100 in PBS for 1 hour. The sections were 
then incubated with anti-GFP primary antibody (prepared in 3% normal 
serum, 0.2% Triton X-100) for 48–72 hours at 4 °C with gentle agitation. 
Immunoperoxidase staining was then performed using the anti-rabbit 
Vectastain Elite ABC kit (Vector Laboratories, Burlingame, CA) as 
described in the manufacturer’s instructions, with 3,3′-diaminobenzidine 
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substrate and nickel–cobalt intensification of the reaction product. 
Brain sections were mounted on slides, coverslipped, and digitized 
using a Scan-Scope slide scanner (Aperio Technologies, Vista, CA). 
Virtual slides were viewed using ImageScope software package (v. 10.0; 
Aperio Technologies), which allowed sections to be viewed at equivalent 
magnifications. Images were digitally adjusted for contrast and brightness 
and assembled into figures in Adobe Photoshop CS, v8.0.
For immunofluorescence colocalization, sections were incubated 
simultaneously with anti-GFP (prepared as described above) and one of 
the following monoclonal antibodies to cellular markers: the neuronal 
marker NeuN (1:500; Chemicon, Temecula, CA); the microglial marker 
OX-42 (1:500; AbD Serotec, Oxford, UK); the astrocyte marker glial 
fibrillary acidic protein (1:4,000; Dako, Glostrup, Denmark), a combination 
of markers for oligodendrocytes consisting of Olig1 (1:500; Chemicon) 
and Olig2 (1:500, Millipore), or the endothelial cell marker RECA-1 
(MCA970R, 1:500; AbD Serotec). Following incubation for 48–72 hours in 
primary antibodies, the sections were rinsed with PBS and blocked again 
for 30 minutes at room temperature in PBS containing 10% goat serum. 
Sections were then co-incubated for 45 minutes at 4 °C with Alexafluor 
488-conjugated goat-anti-rabbit IgG (1:500; Invitrogen, Carlsbad, CA) 
and Alexafluor 594-conjugated goat anti-mouse IgG (1:500; Invitrogen) in 
PBS containing 3% goat serum. For the astrocyte marker, the polyclonal 
glial fibrillary acidic protein antibody was detected using Alexafluor 594-
conjugated goat anti-rabbit IgG (1:500; Invitrogen) while native GFP was 
visualized. Rinsed sections were mounted and fluorescence was visualized 
by confocal microscopy.
Confocal imaging was performed at the Michael Hooker Microscopy 
Center at UNC-Chapel Hill using a Zeiss Axiovert LSM510 laser 
confocal microscope (Carl Zeiss Jena, Jena, Germany). Images were 
processed using Zeiss LSM Image Browser (Carl Zeiss Jena) and Adobe 
Photoshop software. Fluorescein isothiocyanate–albumin and dual-label 
immunofluorescence images were reconstructed from a minimum of five 
consecutive steps in a Z-series taken at 1-μm intervals through the section 
of interest using a ×40 objective.
Biodistribution. All care and procedures were in accordance with the 
Guide for the Care and Use of Laboratory Animals [DHHS publica-
tion no. (NIH)85-23], and all procedures received prior approval by 
the University of North Carolina Institutional Animal Care and Usage 
Committee. Six-month-old female BALB/C mice purchased from 
Jackson Laboratory (Bar Harbor, ME) each were injected in the tail vein 
with 5 × 1010 vg of vector (~2.5 × 1012 vg/kg body weight) in 200 μl of PBS 
with 5% d-sorbitol. Each serotype was injected into three mice. After 10 
days, mice were killed and the brain, lungs, heart, liver, kidney, spleen, 
and gastrocnemius muscle were harvested for biodistribution analysis 
of the GFP vectors. Total DNA from each organ was extracted with a 
DNeasy blood and tissue kit (cat. no. 69506; Qiagen) and total copies 
of GFP and mouse genomic DNA were determined for each by qPCR. 
Biodistribution of clones 32 and 83 were compared to their parent AAV 
serotypes 1, 8, and 9 using Student’s t-test (unpaired, one-tailed), and P 
values are presented in Supplementary Table S3.
qPCR. qPCR was used to determine viral titer and for biodistribution 
studies. All reactions were done using the SyBR Green-based Lightcycler 
fast start DNA master mix (cat. no. 03003230001; Roche) on a Roche 
480 Lightcycler instrument, following the manufacturer’s instructions. 
To prepare virus samples for titer, they were treated with DNase I for 1 
hour, then the DNase I was inactivated with the addition of EDTA and 
heating at 70 °C for 10 minutes. To liberate the encapsidated genomes 
for qPCR analysis, the reaction mixtures were digested with Proteinase 
K for at least 2 hours at 50 °C, then boiled for 10 minutes to inactivate 
the Proteinase K. Samples were diluted in PCR-grade water and used as 
template for qPCR reactions. For GFP or virus quantitation, plasmid DNA 
was used as the standard. For quantification of mouse genomic DNA, 
purified and quantified mouse genomic DNA was used as a standard. All 
 successful reactions gave a single product by melting curve analysis, used 
a  standard curve with an R2 value of 1, and had a reaction run in parallel 
containing no template that gave no product. GFP primers were as fol-
lows: ( forward) 5′-AGCAGCACGACTTCTTCAACTCC-3′, (reverse) 
5′-TGTAGTTGTACTCCAGCTTGTGCC-3′. Rep primers for quan-
titation of library virus were as follows: (forward) 5′-TCCATGGTTTT 
GGGACGTTTCC-3′, (reverse) 5′-TTAGTCCACGCCCACTGGAG-3′. 
LaminB2 primers for quantitation of mouse genomic DNA were as 
 follows: (forward) 5′-GTTAACACTCAGGCGCATGGGCC-3′, (reverse) 
5′-CCATCAGGGTCACCTCTGGTTCC-3′.
suppleMentAry MAterIAl
Figure S1. Mechanical dissociation of AAV2-GFP positive neurons 
from the piriform cortex.
Figure S2. Immunohistochemical analysis of GFP transgene expres-
sion, 2 weeks following injections of AAV1, AAV8 or AAV9 into piriform 
cortex.
Table S1. Recovered clones.
Table S2. Biodistribution of clones 32 and 83 relative to their parent 
serotypes: quantitation.
Table S3. Biodistribution of clones 32 and 83 relative to their parent 
serotypes: statistical significance.
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